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Abstract 
To clarify the long-term efficacy, safety and the cytokine network-modulating 
effects of tacrolimus in myasthenia gravis, medical records of 86 newly diagnosed 
consecutive patients and nine steroid-dependent patients were retrospectively reviewed, 
and peripheral blood mononuclear cells (PBMC) were cultured for the cytokine profile.  
Steroid reduction effects were observed by using tacrolimus, and no serious adverse 
effects were observed.  The culture study showed reduced IL-12, IL-17, IFN-γ, 
GM-CSF, TNF-α and MIP-1β, and elevated IL-10 in the PBMC from patients who 
received tacrolimus, which suggests inhibition of T cells and macrophages, and 
enhancement of type 1 regulatory T cells. 
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1. Introduction 
Myasthenia gravis (MG) is an autoimmune disease in which autoantibodies 
against the nicotinic acetylcholine receptor (AChR) cause a transmission failure at 
neuromuscular junctions (Conti-Fine et al., 2006).  The production of these antibodies 
in B cells depends upon AChR-specific T cells (Fujii and Lindstrom, 1988).  
Long-term corticosteroid treatment markedly improves the outcome of MG therapy 
(Pascuzzi et al., 1984).  Additionally, nonsteroidal immunosuppressive agents, such as 
cyclosporine (Bonifati and Angelini, 1997), azathioprine (Palace et al., 1998), and 
cyclophosphamide (De Feo et al., 2002), have been used in combination with steroids. 
Recently, tacrolimus has also become available for the treatment of MG.  It 
has been reported in non-controlled studies that low-dose administration of tacrolimus 
is effective and safe in combination with steroids for MG (Evoli et al., 2002; Konishi et 
al., 2005; Yoshikawa et al., 2002a).   A distinguishing feature of tacrolimus is that its 
effect appears early after its administration.  The long-term efficacy of tacrolimus has 
also been reported (Konishi et al., 2005; Ponseti et al., 2005).  Tacrolimus is a 
macrolide immunosuppressive agent isolated from Streptomyces tsukubaensis (Kino et 
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al., 1987a) and has been used in the field of organ transplantation (Undre et al., 1999).  
It exhibits immunosuppressive activity by inhibiting production of interleukin (IL) -2 
(Flanagan et al., 1991), which is an early T cell activation factor and stimulates cell 
growth and differentiation (Tocci et al., 1989).  However, the pharmacological effects 
of tacrolimus are not fully understood.  It is thought that there is a significant 
correlation between IgG production and productions of IL-5 and IL-6 by cultured 
peripheral blood mononuclear cells (PBMCs) from patients with MG (Yoshikawa et al., 
2002b).  However the effects of tacrolimus on cytokine production by cultured PBMCs 
have not been evaluated. 
In this study, we examined the long-term efficacy and safety of tacrolimus for 
the treatment of newly diagnosed MG patients in a retrospective case-controlled study.  
We also examined its efficacy and safety for steroid-dependent patients.  In addition, 
we studied cytokine or chemokine production profiles in PBMCs to clarify the 
pharmacological effects of tacrolimus in patients with MG. 
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2. Materials and Methods 
2.1  Clinical study 1.  -Clinical study of steroid-responsive MG patients in the early 
stage- 
2.1.1  Patients 
We retrospectively reviewed the medical records of 86 consecutive MG 
patients admitted to Kanazawa University Hospital between 1993 and 2004 (Figure 1).  
Diagnosis of MG was based on their history, neurological examinations, 
electrophysiological studies (repetitive nerve stimulation test and/or single fiber 
electromyography), and an edrophonium test.  Forty-five sero-positive generalized MG 
patients were enrolled in this study, and were treated with prednisolone (PSL).  Four 
patients who were resistant to PSL therapy (two of four patients received tacrolimus) 
were excluded from this study because they received multiple optional therapies such as 
blood purification therapy (double filtration plasmapheresis, immunoadsorption), high 
dose intravenous gamma-globulin therapy and/or intravenous methylprednisolone pulse 
therapy that prevented us from analyzing the efficacy of tacrolimus.  We also excluded 
12 patients due to their short observation periods (less than 24 months) or insufficient 
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The remaining 29 patients were analyzed in this study (Figure 1), and divided 
into two groups: 13 patients treated with PSL plus tacrolimus and 16 patients treated 
with PSL alone.  Tacrolimus (3 mg/day) has been approved in Japan for MG treatment 
since 2000, therefore, patients who were diagnosed with MG after 2000 were frequently 
treated with PSL and tacrolimus.  There were no significant differences in age, gender, 
the number of thymectomized patients, thymic histology, and MGFA clinical 
classification (Jaretzki et al., 2000) between the two groups (Table 1).   
 
2.1.2  Treatment 
The patients were admitted to our hospital and received general evaluations.  
In those who received a thymectomy, no pharmacological intervention was performed 
before the operation.  PSL was orally administered at an initial dose of 5-10 mg on 
alternate days.  This was gradually increased to 40-80 mg (most patients received 60 
mg) as the maximum maintaining dose on alternate days.  After one-three months of 
maximum dose and clinical and laboratory improvements, the PSL dose was tapered 
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gradually.  The PSL dose was adjusted to the minimum to maintain a normal quality of 
life corresponding to the Minimal Manifestation Status (MMS) of the MGFA 
Postintervention Status (Jaretzki et al., 2000) by the judgment of the neurologist.  
Tacrolimus was started within six months of the initial administration of PSL and 
administered orally at a daily dose of 3 mg, which is approved for MG treatment in 
Japan.  Pyridostigmine bromide at up to 180 mg per day was given if required.   
 
2.1.3  Clinical evaluation 
Clinical classification was performed according to the MGFA classification 
(Jaretzki et al., 2000).  Clinical severity was evaluated according to the MG-ADL scale 
(Wolfe et al., 1999).  PSL dosage was evaluated by converting to a mean daily dose if 
the patient received PSL on alternate days.  Serum AChR antibodies were measured by 
an immunoprecipitation assay using 125I-α-bungarotoxin.  The pre/post treatment ratio 
of serum AChR antibodies (pre/post AChRAb ratio) was calculated, referring to a 
clinical study of azathioprine on MG (Palace et al., 1998).  The PSL dose was 
evaluated at the maximum maintaining phase, 3, 6, 9, 12, 18, 24, 30 and 36 months after 
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the beginning of PSL administration.  The MG-ADL scale was evaluated in the 
pretreatment state, 6, 12, 24 and 36 months after the beginning of PSL administration.  
The pre/post AChRAb ratio was evaluated at 3, 6, 9, 12, 18, 24, 30 and 36 months after 
the administration of PSL. 
 
2.2  Clinical Study 2.  -Clinical study of steroid-dependent MG patients in the chronic 
stage- 
2.2.1  Patients 
Medical records of nine outpatients with MG followed up at our clinic were 
reviewed.  They were administered PSL for a long time to maintain MMS and it was 
difficult to reduce the PSL because of deteriorating myasthenic symptoms.  These nine 
patients were given tacrolimus to enhance the clinical outcome or reduce the PSL dose.  
The characteristics of the patients are listed in Table 2.  All patients had generalized 
MG and were seropositive for AChR antibodies.  They each received a thymectomy 
before the immunosuppressive pharmacological intervention. 
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2.2.2  Treatment 
All patients were administered tacrolimus orally at a daily dose of 3 mg.  The 
PSL dose was adjusted to maintain the MMS of the patients by neurologists.  
Pyridostigmine bromide was given at up to 180 mg per day if required.  No patient in 
this study deteriorated over the three years of clinical treatment. 
 
2.2.3  Clinical evaluation 
PSL dose, clinical severity, and the AChR antibody titer were evaluated as 
described in Clinical Study 1.  PSL dose, MG-ADL scale, and the pre/post AChRAb 
ratio were evaluated at the point of tacrolimus initiation, and at 6, 12, 18, 24, 30 and 36 
months after the administration of tacrolimus.  The same items were also evaluated at 
three and six months before the administration of tacrolimus.   
 
2.2.4  Adverse effecst of tacrolimus 
 The patients completed an adverse-effect questionnaire and received physical 
and laboratory examinations including complete blood count, urea and electrolytes, and 
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liver function tests at each visit.  Unfavorable events occurring after the initiation of 
tacrolimus were described in this study as an adverse effect of tacrolimus. 
 
2.3  Cytokine production of PBMC 
Twenty-one MG patients and eight normal controls were recruited in this study.  
Seven patients were treated with PSL alone, eight with PSL plus tacrolimus, and six 
received no therapy.  Heparinized peripheral venous blood was obtained from patients 
and normal controls.  PBMCs were separated by density gradient centrifugation using 
Histopaque 1077 (Sigma-Aldrich Co Ltd., UK) and washed twice with PBS.  The cells 
were suspended in RPMI1640 medium (Gibco BRL, NY USA) supplemented with 5% 
calf bovine serum (Gibco) and 1% penicillin-streptomycin (Gibco).  The cell 
suspension was adjusted to a concentration of 1 x 106 cells/ml, and cultured in 24-well 
culture plates in a final volume of 1 ml at 37ºC in 5% CO2/ 95% air for seven days. 
The culture medium was analyzed for 14 different cytokines and chemokines, 
namely interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12 p70, IL-13, IL-17, 
interferon (IFN)-γ, tumor necrosis factor (TNF)-α, granulocyte colony-stimulating 
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factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and 
macrophage inflammatory protein 1β (MIP-1β), using a Bio-Plex multiplex suspension 
array system (Bio-Rad Laboratories, Hercules, CA USA), which utilizes Luminex 
fluorescent-bead-based technology, according to the manufacturer’s instructions (de 
Jager et al., 2003; Kellar et al., 2001). 
 
2.4  Statistical analysis 
The clinical parameters were assessed by non-parametric analyses.  To 
determine the time point when the effect of tacrolimus appeared, the PSL dosages in the 
groups of PSL alone and of PSL plus tacrolimus were analyzed by the Mann-Whitney U 
test (exact test) in Clinical Study 1.  An intrapatient comparison was done with the 
Wilcoxon signed-rank test by comparing the value at each time point with the beginning 
point of tacrolimus in Clinical Study 2.  Differences in cytokine levels between the 
four groups were evaluated for normal distribution.  In cases of normal distribution, 
the Tukey-Kramer HSD test was applied after oneway ANOVA.  In cases of 
non-normal distribution, the Kruskal-Wallis test was applied. 
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2.5  Ethics approval 
Clinical studies 1 and 2 were carried out following the ethical code of 
Kanazawa University Hospital.  The cytokine study protocol was approved by the 
Ethics Committee of Kanazawa University, and full informed consent was obtained 
from all patients.
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3. Results 
3.1  Clinical Study 1. 
The changes in PSL dose, MG-ADL scale, and the pre/post AChRAb ratio are 
shown in Figure 2.  The median PSL dose expressed as the daily amount during the 
maximum maintenance phase was 30 mg in both groups.  The dose of PSL was 
gradually reduced, and there were no significant differences until 24 months from the 
beginning of PSL treatment between the two groups.  However, the dose was 
significantly lower in patients treated with PSL plus tacrolimus than with PSL alone at 
30 and 36 months (median dose 1.25 vs. 6.0 mg at 30 months, p<0.05, 0.0 vs. 5.5 mg at 
36 months, p<0.05). 
Median MG-ADL scales before treatment were 5.0 and 7.0 in the groups 
treated with PSL plus tacrolimus and PSL alone respectively, and there was no 
significant difference between them.  Six months from the beginning of PSL therapy, 
all the patients achieved MMS and median MG-ADL scales were 0.0 and 0.5 in those 
treated with PSL plus tacrolimus and PSL alone respectively.  As a result, every patient 
remained in MMS throughout the course. 
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The level of AChR antibodies decreased to about a quarter of the pretreatment 
value within six months in both groups.  The pre/post AChRAb ratio remained around 
20% in the group treated with PSL alone whereas it gradually dropped in the group 
treated with PSL plus tacrolimus.  There were statistical differences at 30 months (6.32 
vs 12.75, p<0.05) and 36 months (6.65 vs 15.38, p<0.05) from the beginning of 
treatment (Figure 2). 
 
3.2  Clinical Study 2. 
The changes in PSL dose, MG-ADL scale, and pre/post AChRAb ratio are 
shown in Figure 3.  The median dose of PSL at six and three months before tacrolimus 
was first given was not significantly different from that at the beginning of tacrolimus 
treatment (12.5 mg at each point).  The PSL dose was significantly lower at six months 
from the administration of tacrolimus (9.0 mg, p<0.01) and reduced gradually for three 
years (8.0 mg at 36 month, p<0.05).  There were no marked changes in the MG-ADL 
scale and the pre/post AChRAb ratio over the three years. 
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3.3  Adverse effects of tacrolimus in Clinical Studies 1 and 2. 
Five adverse effects were observed which were considered to be related to 
tacrolimus (Table 3).  A decrease in lymphocyte number was observed in a 56-year old 
female after three weeks of tacrolimus administration.  She had received 60 mg of PSL 
on alternate days and radiation therapy for thymoma as an aftertreatment for extended 
thymectomy.  After completion of radiation therapy and reducing tacrolimus to daily 
dose of 2 mg, the lymphocyte number recovered.  Other adverse effects were as 
follows: acute pyelonephritis, hyperkalemia, and decreased creatinine clearance, as well 
as elevation of glycohemoglobin.  These symptoms disappeared after reducing the 
dose of tacrolimus.  No malignancy developed in either clinical study during the 
observation periods. 
 
3.4  Cytokine production of PBMC 
The characteristics of the patients enrolled in this study are listed in Table 4.  
There were no differences between the four groups in age or gender.  The mean PSL 
dose did not differ statistically between the patients treated with PSL alone and those 
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treated with PSL plus tacrolimus.  There was no difference between the AChR 
antibody titers in the three subgroups of MG patients. 
Levels of cytokines produced by 1 x 106 PBMCs, analyzed by Tukey-Kramer 
HSD test after oneway ANOVA, are shown in Figure 4.  IL-4, IL-17 and IFN-γ levels 
were significantly lower in the group treated with PSL plus tacrolimus compared to the 
normal control.  IL-12 p70, GM-CSF, TNF-α and MIP-1β levels were significantly 
different between groups (Kruskal-Wallis test).  IL-10 levels were significantly higher 
in the PSL plus tacrolimus group than in the other groups.  The levels of the remaining 
cytokines, IL-1β, IL-2, IL-6, IL-7, IL13 and G-CSF, did not differ between the groups.
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4. Discussion 
The prognosis for MG has improved in recent years with the introduction of 
new immunosuppressants (Phillips and Torner, 1996).  In addition, modern critical 
care service and improvements in diagnostic procedures leading to earlier treatment also 
contributed to a good MG outcome.  However, quality of life (QOL) was not adequate 
because of persistent myasthenic symptoms (Rostedt et al., 2006).  Corticosteroids are 
widely used and are effective in the treatment of MG but have various side effects.  
Some non-steroidal immunosuppressants can achieve clinical improvements or reduce 
the side effects of corticosteroids, tacrolimus being one prime example (Evoli et al., 
2002; Konishi et al., 2005; Yoshikawa et al., 2002a). 
We showed that tacrolimus was an adjunct to PSL in the treatment of 
antibody-positive generalized MG.  Namely, it reduced the maintenance dose of PSL 
without serious side effects in two clinical studies.  In Clinical Study 1, all patients had 
generalized MG and were seropositive for the AChR antibody.  In addition, both 
groups of patients were matched for age, gender, thymic histology, and severity.  
Furthermore, all patients were followed up in our affiliated institutions.  Therefore, we 
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consider these two groups to be quite similar in terms of clinical background and 
comparable for showing the efficacy of tacrolimus.   
Recently, a randomized trial showing the efficacy of low-dose tacrolimus for 
the treatment of untreated de novo MG patients was reported (Nagane et al., 2005).  
Although our study is retrospective and we did not reduce PSL dose followed by a 
designed protocol, their results are consistent with our finding.  The utilization of 
low-dose tacrolimus for de novo MG patients from early on in the treatment reduces the 
maintenance dose of PSL.  In Clinical Study 1, three patients stopped receiving PSL at 
24 months and six patients at 30 months from the beginning of PSL treatment in the 
group treated with PSL plus tacrolimus, whereas only one patient discontinued 
receiving PSL in the group treated with PSL alone.  Furthermore, two patients who 
received PSL plus tacrolimus, discontinued PSL therapy, and after that tacrolimus was 
withdrawn at 30 months from the beginning of PSL treatment.  The administration of 
tacrolimus from early on in the treatment of MG might be an option to reduce the 
maintenance dose of PSL long-term.  In addition, the PSL dose was automatically 
increased up to 60 mg on alternate days according to our standard protocol for the 
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treatment of MG; however, the maximum PSL dose might be reduced significantly by 
using tacrolimus.  Further studies are required to confirm our hypothesis. 
We also evaluated the efficacy of tacrolimus for steroid-dependent patients 
with MG from the standpoint of a long-term treatment strategy (Clinical Study 2).  
There were no changes in the PSL dose before the administration of tacrolimus for as 
long as six months and the dose significantly decreased after its administration.  These 
findings indicate that nine patients enrolled in this study were steroid-dependent and in 
these cases, the dose of PSL was successfully reduced by the administration of 
tacrolimus.  A previous study on tacrolimus for the treatment of MG indicated that 
clinical improvement was achieved so rapidly that muscle strength improved two weeks 
after the initiation of tacrolimus (Yoshikawa et al., 2002a).  In the present study, 
patients remained in MMS during the observation periods; however, the PSL dose was 
reduced within six months from the beginning of tacrolimus administration. 
The MG-ADL scale showed no significant differences during the course, and 
the points were quite low.  It is conceivable that the scale at the start point was already 
low and the patients remained well during the course, so no statistical significance 
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appeared.  Tacrolimus could be useful for steroid-dependent cases to reduce the dose 
of steroids while maintaining MMS. 
Infection and renal toxicity have been reported at the high doses of tacrolimus 
used for organ transplantation.  In this study, five mild adverse effects were reported; 
lymphocytopnea, acute pyelonephritis, hyperkalemia, decreased creatinine clearance 
and elevated glycohemoglobin.  These effects were transient and resolved by 
appropriate management and no serious problem occurred.  Taken together with a 
previous report (Konishi et al., 2005), long-term low-dose administration of tacrolimus 
is an efficacious and safe treatment for MG.   
The immunosuppressive activity of tacrolimus is considered to be mediated by 
the selective inhibition of helper T cell activation (Kino et al., 1987b).  Tacrolimus 
binds to FK506-binding protein 12 (FKBP12) which is the intracellular receptor of 
tacrolimus (Harding et al., 1989) and the FKBP12-tacrolimus complex inhibits 
dephosphorylation of nuclear factor (NF)-AT by calcineurin (Liu et al., 1991).  As a 
result, inhibition of calcineurin prevents translocation of NF-AT to the nucleus, which is 
essential for transcription of IL-2 (Flanagan et al., 1991). 
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On the other hand, various cytokines, including both T helper 1 (Th1) and T 
helper 2 (Th2), play important roles in the pathogenesis of MG (Zhang et al., 1997); 
however, details on each cytokine produced by PBMCs in MG patients and the effects 
of tacrolimus on cytokine production are still unclear. 
To elucidate the mechanism by which tacrolimus acts on the immune system, 
we evaluated the production of various cytokines that constitute the immune network.  
The secretion of IL-12, IL-17, GM-CSF, IFN-γ, TNF-α, and MIP-1β decreased in 
patients treated with PSL plus tacrolimus.  IL-17, IFN-γ, and GM-CSF are mainly 
secreted from helper T cells, especially Th1 cells, lead to the proliferation and activation 
of macrophages.  We also showed decreased secretions of IL-12, TNF-α and 
MIP-1β, which are mainly produced in activated macrophages.  These results suggest 
that tacrolimus specifically inhibits Th1 cells, and as a consequence reduces the activity 
of macrophages.  A recent study showed that treatment with tacrolimus inhibited the 
expression of Th1 cytokine mRNA in lupus-prone mice (Sugiyama et al., 2004). 
A recent study showed that toll-like receptor (TLR) antagonists facilitated 
production of IL-23 by activated macrophages, which induced T cells to secrete IFN-γ 
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and IL-17 (Hoeve et al., 2006).  The IFN-γ secreted from T cells induces macrophages 
to secrete IL-12, which inhibit the secretion of IL-17 by activated T cells without 
affecting IFN-γ production.  Considering that TNF-α and MIP-1β are produced from 
activated macrophages, our results indicate that tacrolimus inhibits the activation of 
macrophages, and down-regulates T cell activities.   
 Another interesting result of the current study is the enhanced secretion of IL-10 in 
the patients treated with PSL plus tacrolimus.  IL-10 is mainly produced by Th2 cells 
(Fiorentino et al., 1989), which also produce IL-4, IL-5, and IL-13.  Type 1 regulatory T 
(Tr1) cells are also representative of IL-10-producing cells, and can secrete transforming 
growth factor (TGF) –β, leading to peripheral immunotolerance (Groux et al., 1997; 
Roncarolo and Levings, 2000).  A previous report showed tacrolimus enhances the 
expression of TGF-β1 mRNA and production of TGF-β1 protein (Khanna et al., 1999).  
Therefore, it is conceivable that IL-10-producing Tr1 cells might be activated by the 
tacrolimus.  In our study, no enhanced production of such Th2 cytokines other than 
IL-10 was observed in the group treated with PSL plus tacrolimus.  Since IL-10 has been 
described as a strong inhibitor of antigen presentation (de Waal Malefyt et al., 1991), the 
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inhibition of AChRAb production might be caused by the down-regulation of MHC class 
II enhanced by IL-10 secretion from activated Tr1 cells. 
 The value of this clinical study is limited by its retrospective study design and 
small number of patients, but tacrolimus proved to be a useful for treatment of MG, and 
was tolerable from our results.  Currently, a prospective double-blind randomized 
controlled multi-center study on tacrolimus for the treatment of MG is ongoing in Japan 
and the results will give us clearer information regarding the clinical efficacy of 
tacrolimus.  Our study on cytokine production by PBMC aids understanding of the 
pharmacological effects of tacrolimus. 
 In conclusion, low-dose tacrolimus is a useful and safe immunosuppressive 
therapy for the treatment of MG long-term.  It is suggested that the immunosuppressive 
effects of tacrolimus are achieved by the inhibition of activated T cells and macrophages 
via the cytokine network, and by the enhancement of activities of Tr1 cells.  Our results 
provide useful information for further clinical and experimental studies on the treatment 
of MG. 
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Figure Legends 
Figure 1.  The 86 patients evaluated at Kanazawa University Hospital from 1993 to 
2004.  Forty-five MG patients were selected because they had generalized MG, were 
seropositive for the anti-AChR antibody, and were receiving PSL therapy.  Four 
patients were excluded because they were receiving multiple optional therapies.  
Twelve of these patients were excluded because of a short observation period or 
insufficient clinical data.  The remaining 29 patients were analyzed in Clinical Study 1. 
 
Figure 2.  The clinical course of PSL dose (A), MG-ADL scale (B), and anti-AChR 
antibody (C) in Clinical Study 1.  The course of the anti-AChR antibody is expressed 
as a ratio (pre/post AChRAb ratio).  Each mark indicates the median value of that item.  
There were no significant differences between the two groups in PSL dose and pre/post 
AChRAb ratio for 24 months from the beginning of PSL; however, the PSL dose and 
pre/post AChRAb ratio were significantly lower in the group treated with tacrolimus at 
30 and 36 months from the beginning of PSL administration.  There were no 
significant differences during the course between the two groups in terms of MG-ADL 
Furukawa et al. -33- 
scale. 
 
Figure 3.  The clinical course of PSL dose (A), MG-ADL scale (B), and anti-AChR 
antibody (C) in Clinical Study 2.  The course of the anti-AChR antibody is expressed 
as a ratio (pre/post AChRAb ratio).  Each mark indicates the median value of that item.  
Compared with the PSL dose at the point of tacrolimus initiation (0M), the PSL dose 
was significantly lower at six months from the beginning of tacrolimus and gradually 
reduced during the course.  Conversely, there were no significant differences in PSL 
dose before tacrolimus initiation.  MG-ADL scale and the pre/post AChRAb ratio 
showed no significant differences during the observation period. 
 
Figure 4.  Cytokine levels (A. IL-4, B. IL-10, C. IL-17, D. IFN-γ) produced by 1 x 
106 peripheral blood mononuclear cells from MG patients treated with PSL alone, MG 
patients treated with PSL plus tacrolimus, untreated MG patients, and normal controls 
assessed by the multiplexed fluorescent bead-based immunoassay.  Horizontal bars 
placed in each group indicate the mean value of the cytokine or chemokine.  * 
Furukawa et al. -34- 
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Table 1. 
The characteristics of the patients in clinical study 1. 
Treatment 




Gender (male/female) 4/9 6/10 
Age (y): mean ± SD (range) 44.8 ± 21.6 (15-79) 47.9 ± 23.3 (11-83) 
Thymectomized patient: number (%) 11 (84.6 %) 15 (93.8 %) 
Thymic histology: (number of patient)   
  Thymoma 3 6 
  Thymic hyperplasia 7 4 
  Thymic involution 1 5 
MGFA classification at disease onset: (number)   
  IIa 6 6 
  IIb 3 3 
  IIIa 2 3 
  IIIb 2 4 
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Table 2. 
The characteristics of the patients in clinical study 2. 
 Patients, n=9 
Gender (male/female) 3/6 
Age (y): mean ± SD (range) 48.0 ± 16.1 (26-74) 
Disease duration (y): mean ± SD (range) 12.6 ± 11.2 (3-36) 
Thymectomized patient: number (%) 9 (100%) 
Time from thymectomy (y): mean ± SD (range) 10.2 ± 8.0 (2-24) 
Thymic histology: (number)  
  Thymoma 3 
  Thymic hyperplasia 3 
  Thymic involution 3 
MGFA classification at disease onset: (number)  
  IIa 3 
  IIb 2 
  IIIa 1 
  IIIb 3 
AChR antibody nmol/l: mean ± SD (range)  
  at the beginning of tacrolimus 38.5 ± 37.0 (0.3-118) 
  at 36 months from the beginning of tacrolimus 28.5 ± 24.3 (0.3-66.0) 
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Table 3 
Adverse events due to tacrolimus treatment 
patient age at onset of 
adverse effect   
gender event  time from 
tacrolimus initiation
management Duration to 
recovery 
1 56 F Lymphocytopnea  
(300 /μl) 
3 W tacrolimus reduction 
to 2mg/day  
2 M 
2 51 M pyelonephritis 28 M antibiotics a few days 
3 35 M hyperkalemia 18 M tacrolimus reduction 
to 2mg/day 
1 M 
4 14 F decreased creatinine 
clearance (50ml/min) 
5 M tacrolimus reduction 
to 2mg/day 
2 M 
5 43 F increased 
glycohemoglobin 
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Table 4 
Classification by patient treatment of in the cytokine study. 
Patients with MG  





Gender (male/female) 3/4 3/5 2/4 3/5 
Age (y): mean ± SD 58.7 ± 17.0 49.6 ± 18.4 52.6 ± 24.3 34.6 ± 6.5 
PSL dose (mg/day): mean ± SD 6.4 ± 3.5 7.2 ± 2.9 0 0 
Tacrolimus dose (mg/day): mean ± SD 0 2.7 ± 0.5 0 0 
AChR antibody (nmol/l): mean ± SD 48.0 ± 55.6 44.5 ± 54.7 45.6 ± 71.2 0 








Ocular MG, n=22Generalized MG, n=64 
With PSL therapy, n=45 Without PSL therapy, n=7 
Seropositive MG, n=52 
Exclusion, n=4, multiple therapy 
Exclusion, n=12, short observation 
Patients analyzed in Clinical Study 1, n=29
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